Myeloid Leukemia News and Research RSS Feed - Myeloid Leukemia News and Research

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
McMaster University researchers take a giant leap in detecting early stages of leukemia

McMaster University researchers take a giant leap in detecting early stages of leukemia

McMaster University researchers have taken a giant leap in identifying the early stages of a deadly cancer and predicting how it will develop in individuals. [More]
Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. [More]
Researchers reveal inherited genetic errors across 12 cancer types

Researchers reveal inherited genetic errors across 12 cancer types

Researchers long have known that some portion of the risk of developing cancer is hereditary and that inherited genetic errors are very important in some tumors but much less so in others. [More]
Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

Researchers at Penn State College of Medicine, working with Chinese and American colleagues, have discovered a novel way to enhance and restore cancer suppressor activity in B-cell acute lymphoblastic leukemia, resulting in better outcomes in a pre-clinical model of the disease. The finding could pave the way for a new class of drugs for this and other forms of leukemia. [More]
TET proteins needed to maintain genome instability, say researchers

TET proteins needed to maintain genome instability, say researchers

Members of the TET (short for ten-eleven translocation) family have been known to function as tumor suppressors for many years, but how they keep a lid on the uncontrolled cell proliferation of cancer cells had remained uncertain. Now, researchers at the La Jolla Institute for Allergy and Immunology demonstrate that TET proteins collectively constitute a major class of tumor suppressors and are required to maintain genome instability. [More]
Researchers find new significant link between NPM protein and development of AML

Researchers find new significant link between NPM protein and development of AML

A team of researchers from the National University of Singapore has found a new significant correlation between the protein nucleophosmin (NPM) and the development of an aggressive form of blood cancer called acute myeloid leukemia (AML). [More]
First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando. [More]
New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers. [More]
Discovery may lead to potential new therapeutic approach to eradicate blood cancers

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

An international team of scientists, headed by researchers at UC San Diego School of Medicine and UC San Diego Moores Cancer Center, report that decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs). [More]
Scientists map out genes that keep cancer cells alive

Scientists map out genes that keep cancer cells alive

Scientists have mapped out the genes that keep our cells alive, creating a long-awaited foothold for understanding how our genome works and which genes are crucial in disease like cancer. [More]
Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma. [More]
Potential new drug target for acute myeloid leukemia

Potential new drug target for acute myeloid leukemia

New treatment options are badly needed for acute myeloid leukemia, a relatively rare form of cancer. The malignancy begins in the bone marrow, and from there can spread rapidly to the bloodstream, depriving the body of the essential blood cells that carry oxygen and fight infections. [More]
TSRI researchers find way to change leukemia cells into leukemia-killing immune cells

TSRI researchers find way to change leukemia cells into leukemia-killing immune cells

Scientists at The Scripps Research Institute have found a way to change leukemia cells into leukemia-killing immune cells. The surprise finding could lead to a powerful new therapy for leukemia and possibly other cancers. [More]
Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Preclinical experiments led by a team of researchers at VCU Massey Cancer Center have shown that blocking the production of a protein known as chromodomain helicase DNA-binding protein 4 (CHD4) may help increase the effectiveness of first-line treatments for acute myeloid leukemia (AML), a particularly lethal blood cancer that is increasing in incidence among older adults. [More]

Scientists create 3D image of key protein involved in blood and other cancer development

Scientists at the Walter and Eliza Hall Institute have created the first three-dimensional image of a key protein known to be involved in the development of blood and other cancers. [More]
Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals. [More]
Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. [More]
Study reveals how leukemia cells evade deadly effects of BRD4 inhibitors

Study reveals how leukemia cells evade deadly effects of BRD4 inhibitors

BRD4 inhibitors are among the most promising new agents in cancer therapy that are currently evaluated in clinical trials. [More]

Scientists identify a gene that can cause more aggressive cancer in AML patients

University of Manchester scientists have identified a gene - FOXC1 - that, if switched on, causes more aggressive cancer in a fifth of acute myeloid leukaemia (AML) patients, according to a Cancer Research UK study published in the journal Cancer Cell, today (Monday). [More]
Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers. [More]
Advertisement
Advertisement